YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based research on a cancer treatment.

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...